Aclaris Therapeutics, Inc. (ACRS)
USD 1.27
(6.3%)
USD 1.27
(6.3%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -97.35 Million USD | -14.33% |
| 2022 | -85.15 Million USD | -30.24% |
| 2021 | -65.38 Million USD | -28.43% |
| 2020 | -50.91 Million USD | 54.16% |
| 2019 | -111.05 Million USD | 17.99% |
| 2018 | -135.41 Million USD | -86.98% |
| 2017 | -72.42 Million USD | -49.12% |
| 2016 | -48.56 Million USD | -135.0% |
| 2015 | -20.66 Million USD | -142.2% |
| 2014 | -8.53 Million USD | -62.32% |
| 2013 | -5.25 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -13.63 Million USD | -236.82% |
| 2024 Q2 | -12.55 Million USD | 7.9% |
| 2023 Q4 | -4.04 Million USD | 87.18% |
| 2023 Q3 | -31.57 Million USD | 0.75% |
| 2023 Q2 | -31.81 Million USD | -3.57% |
| 2023 FY | -97.35 Million USD | -14.33% |
| 2023 Q1 | -30.71 Million USD | -39.76% |
| 2022 Q4 | -21.97 Million USD | -17.7% |
| 2022 Q2 | -24.39 Million USD | -21.32% |
| 2022 Q1 | -20.1 Million USD | 12.17% |
| 2022 FY | -85.15 Million USD | -30.24% |
| 2022 Q3 | -18.67 Million USD | 23.45% |
| 2021 FY | -65.38 Million USD | -28.43% |
| 2021 Q3 | -20.29 Million USD | -12.71% |
| 2021 Q4 | -22.89 Million USD | -12.8% |
| 2021 Q1 | -28.52 Million USD | -110.39% |
| 2021 Q2 | -18 Million USD | 36.89% |
| 2020 Q2 | -11.38 Million USD | 26.6% |
| 2020 FY | -50.91 Million USD | 54.16% |
| 2020 Q4 | -13.56 Million USD | -29.57% |
| 2020 Q1 | -15.5 Million USD | 10.28% |
| 2020 Q3 | -10.46 Million USD | 8.05% |
| 2019 Q2 | -49.79 Million USD | -33.36% |
| 2019 Q3 | -22.86 Million USD | 54.08% |
| 2019 FY | -111.05 Million USD | 17.99% |
| 2019 Q4 | -17.28 Million USD | 24.41% |
| 2019 Q1 | -37.33 Million USD | 4.36% |
| 2018 Q3 | -33.45 Million USD | -4.6% |
| 2018 FY | -135.41 Million USD | -86.98% |
| 2018 Q4 | -39.03 Million USD | -16.71% |
| 2018 Q2 | -31.97 Million USD | -3.33% |
| 2018 Q1 | -30.94 Million USD | -21.64% |
| 2017 Q2 | -15.29 Million USD | -18.29% |
| 2017 Q3 | -18.75 Million USD | -22.63% |
| 2017 Q4 | -25.44 Million USD | -35.65% |
| 2017 FY | -72.42 Million USD | -49.12% |
| 2017 Q1 | -12.93 Million USD | -11.21% |
| 2016 Q4 | -11.62 Million USD | -7.54% |
| 2016 Q3 | -10.81 Million USD | 16.76% |
| 2016 FY | -48.56 Million USD | -135.0% |
| 2016 Q1 | -13.13 Million USD | -173.62% |
| 2016 Q2 | -12.98 Million USD | 1.14% |
| 2015 Q3 | -10.64 Million USD | -309.86% |
| 2015 Q1 | -2.62 Million USD | -1.04% |
| 2015 Q4 | -4.8 Million USD | 54.87% |
| 2015 Q2 | -2.59 Million USD | 1.26% |
| 2015 FY | -20.66 Million USD | -142.2% |
| 2014 FY | -8.53 Million USD | -62.32% |
| 2014 Q3 | -2.66 Million USD | -62.86% |
| 2014 Q4 | -2.6 Million USD | 2.25% |
| 2014 Q2 | -1.63 Million USD | 0.0% |
| 2014 Q1 | -1.63 Million USD | 0.0% |
| 2013 FY | -5.25 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Applied DNA Sciences, Inc. | -10.95 Million USD | -788.838% |
| Aspira Women's Health Inc. | -18.85 Million USD | -416.428% |
| Biodesix, Inc. | -41.34 Million USD | -135.492% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -3653.757% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1121.049% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1121.049% |
| Bionano Genomics, Inc. | -215.24 Million USD | 54.769% |
| CareDx, Inc | -101.9 Million USD | 4.458% |
| Check-Cap Ltd. | -19.28 Million USD | -404.78% |
| Castle Biosciences, Inc. | -67.97 Million USD | -43.221% |
| DarioHealth Corp. | -56.18 Million USD | -73.267% |
| Exact Sciences Corporation | -215.01 Million USD | 54.72% |
| Fulgent Genetics, Inc. | -72.69 Million USD | -33.925% |
| Guardant Health, Inc. | -564.72 Million USD | 82.76% |
| ICON Public Limited Company | 956.15 Million USD | 110.182% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 108.874% |
| Illumina, Inc. | -1.06 Billion USD | 90.893% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -846.76% |
| iSpecimen Inc. | -11.16 Million USD | -771.644% |
| Standard BioTools Inc. | -76.6 Million USD | -27.098% |
| MDxHealth SA | -27.32 Million USD | -256.267% |
| 23andMe Holding Co. | -321.35 Million USD | 69.704% |
| Medpace Holdings, Inc. | 336.82 Million USD | 128.904% |
| Myriad Genetics, Inc. | -123.7 Million USD | 21.296% |
| Mainz Biomed B.V. | -26.64 Million USD | -265.39% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -825.382% |
| NeoGenomics, Inc. | -107.73 Million USD | 9.634% |
| Neogen Corporation | 58.66 Million USD | 265.96% |
| Inotiv, Inc. | -81.46 Million USD | -19.515% |
| Natera, Inc. | -446.24 Million USD | 78.183% |
| OpGen, Inc. | -15.68 Million USD | -520.564% |
| OPKO Health, Inc. | -157.02 Million USD | 37.997% |
| Psychemedics Corporation | -2.92 Million USD | -3233.002% |
| Prenetics Global Limited | -52.51 Million USD | -85.394% |
| Prenetics Global Limited | -52.51 Million USD | -85.394% |
| Precipio, Inc. | -7.62 Million USD | -1177.651% |
| Personalis, Inc. | -109.93 Million USD | 11.442% |
| RadNet, Inc. | 98.69 Million USD | 198.642% |
| Sera Prognostics, Inc. | -39.82 Million USD | -144.487% |
| Sotera Health Company | 276.69 Million USD | 135.186% |
| Neuronetics, Inc. | -30.55 Million USD | -218.639% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -2140.152% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -2140.152% |
| Trinity Biotech plc | -27.04 Million USD | -259.982% |
| T2 Biosystems, Inc. | -49.66 Million USD | -96.031% |
| Twist Bioscience Corporation | -220.83 Million USD | 55.913% |
| Exagen Inc. | -22.83 Million USD | -326.313% |